+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anticancer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025

  • ID: 4851413
  • Report
  • January 2018
  • Region: Global
  • 226 pages
  • Transparency Market Research
1 of 2

Global Anticancer drugs Market: Scope and Research Methodology

This report on the global anticancer drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment and sub-segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global anticancer drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global anticancer drugs market.

Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year. Market size estimations involved in-depth study of features of different type of drugs, therapies and cancer types. Additionally, market related factors such as rise in preference of targeted therapies, high prevalence rate of cancer, rise in per capita healthcare expenditure etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Anticancer drugs Market: Segmentation

Cancer is caused due to abnormal growth of the cells. Anticancer drugs are also known as antineoplastic drugs. These drugs prevents and inhibits the growth of cancer cells.

Based on drug types, global anticancer drugs market is segmented into cytotoxic drugs, targeted drugs, and hormonal drugs. The targeted drugs segment is further segmented into monoclonal antibodies, tyrosine kinase inhibitors and others. The segment is anticipated to hold a significant share of the global market. The targeted drugs have a significant demand and is expected to continue dominating the global market throughout the forecast period.

Based on therapy type, global anticancer drugs market is segmented into chemotherapy, targeted therapy, immunotherapy and others. Targeted therapy held the highest share of the market and is anticipated to dominate the market during the forecast period. Side effects of chemotherapy and specificity of the targeted drug are the factors driving the growth of global market.

Based on cancer types, the global anticancer drugs market is segmented into lung cancer, breast cancer, leukemia, colorectal cancer and others. The lung cancer segment is expected to expand at the fast rate due to high prevalence of the disease worldwide.

Anticancer drugs Market: Geographical and Competitive Dynamics

Geographically, the global anticancer drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region.

The report also profiles major players in the anticancer drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc. etc.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Anticancer Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.3.4. Trends
4.4. Global Anticancer Drugs Market Analysis and Forecasts, 2015-2025
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
4.6. Value Chain Analysis
4.7. Market Outlook
4.8. Pipeline Analysis
4.9. Disease Overview
4.10. Evolution of Cancer Therapies

5. Global Anticancer Drugs Market Analysis and Forecasts, By Drug Type
5.1. Introduction & Definition
5.2. Key Findings/Developments
5.3. Market Value Forecast By Drug Type , 2015-2025
5.3.1. Cytotoxic Drugs
5.3.1.1. Alkylating Agents
5.3.1.2. Antimetabolites
5.3.1.3. Others
5.3.2. Targeted Drugs
5.3.2.1. Monoclonal Antibodies
5.3.2.2. Tyrosine Kinase Inhibitors
5.3.2.3. Others
5.3.3. Hormonal Drugs
5.4. Market Attractiveness By Drug Type

6. Global Anticancer Drugs Market Analysis and Forecasts, By Therapy Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast By Therapy Type , 2015-2025
6.3.1. Chemotherapy
6.3.2. Targeted Therapy
6.3.3. Immunotherapy
6.3.4. Others
6.4. Market Attractiveness By Therapy Type

7. Global Anticancer Drugs Market Analysis and Forecasts, By Cancer Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast By Cancer Type , 2015-2025
7.3.1. Lung Cancer
7.3.2. Breast Cancer
7.3.3. Leukemia
7.3.4. Colorectal Cancer
7.3.5. Others
7.4. Market Attractiveness By Cancer Type

8. Global Anticancer Drugs Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness By Region

9. North America Anticancer Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Key Trends
9.2. Market Value Forecast By Drug Type , 2015-2025
9.2.1. Cytotoxic Drugs
9.2.1.1. Alkylating Agents
9.2.1.2. Antimetabolites
9.2.1.3. Others
9.2.2. Targeted Drugs
9.2.2.1. Monoclonal Antibodies
9.2.2.2. Tyrosine Kinase Inhibitors
9.2.2.3. Others
9.2.3. Hormonal Drugs
9.3. Market Value Forecast By Therapy Type , 2015-2025
9.3.1. Chemotherapy
9.3.2. Targeted Therapy
9.3.3. Immunotherapy
9.3.4. Others
9.4. Market Value Forecast By Cancer Type , 2015-2025
9.4.1. Lung Cancer
9.4.2. Breast Cancer
9.4.3. Leukemia
9.4.4. Colorectal Cancer
9.4.5. Others
9.5. Market Value Forecast By Country, 2015-2025
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Type
9.6.2. By Therapy Type
9.6.3. By Cancer Type
9.6.4. By Country

10. Europe Anticancer Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Key Trends
10.2. Market Value Forecast By Drug Type , 2015-2025
10.2.1. Cytotoxic Drugs
10.2.1.1. Alkylating Agents
10.2.1.2. Antimetabolites
10.2.1.3. Others
10.2.2. Targeted Drugs
10.2.2.1. Monoclonal Antibodies
10.2.2.2. Tyrosine Kinase Inhibitors
10.2.2.3. Others
10.2.3. Hormonal Drugs
10.3. Market Value Forecast By Therapy Type , 2015-2025
10.3.1. Chemotherapy
10.3.2. Targeted Therapy
10.3.3. Immunotherapy
10.3.4. Others
10.4. Market Value Forecast By Cancer Type , 2015-2025
10.4.1. Lung Cancer
10.4.2. Breast Cancer
10.4.3. Leukemia
10.4.4. Colorectal Cancer
10.4.5. Others
10.5. Market Value Forecast By Country/Sub-region, 2015-2025
10.5.1. U.K.
10.5.2. Germany
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Type
10.6.2. By Therapy Type
10.6.3. By Cancer Type
10.6.4. By Country/Sub-region

11. Asia Pacific Anticancer Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Key Trends
11.2. Market Value Forecast By Drug Type , 2015-2025
11.2.1. Cytotoxic Drugs
11.2.1.1. Alkylating Agents
11.2.1.2. Antimetabolites
11.2.1.3. Others
11.2.2. Targeted Drugs
11.2.2.1. Monoclonal Antibodies
11.2.2.2. Tyrosine Kinase Inhibitors
11.2.2.3. Others
11.2.3. Hormonal Drugs
11.3. Market Value Forecast By Therapy Type , 2015-2025
11.3.1. Chemotherapy
11.3.2. Targeted Therapy
11.3.3. Immunotherapy
11.3.4. Others
11.4. Market Value Forecast By Cancer Type , 2015-2025
11.4.1. Lung Cancer
11.4.2. Breast Cancer
11.4.3. Leukemia
11.4.4. Colorectal Cancer
11.4.5. Others
11.5. Market Value Forecast By Country/Sub-region, 2015-2025
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Drug Type
11.6.2. By Therapy Type
11.6.3. By Cancer Type
11.6.4. By Country/Sub-region

12. Latin America Anticancer Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Key Trends
12.2. Market Value Forecast By Drug Type , 2015-2025
12.2.1. Cytotoxic Drugs
12.2.1.1. Alkylating Agents
12.2.1.2. Antimetabolites
12.2.1.3. Others
12.2.2. Targeted Drugs
12.2.2.1. Monoclonal Antibodies
12.2.2.2. Tyrosine Kinase Inhibitors
12.2.2.3. Others
12.2.3. Hormonal Drugs
12.3. Market Value Forecast By Therapy Type , 2015-2025
12.3.1. Chemotherapy
12.3.2. Targeted Therapy
12.3.3. Immunotherapy
12.3.4. Others
12.4. Market Value Forecast By Cancer Type , 2015-2025
12.4.1. Lung Cancer
12.4.2. Breast Cancer
12.4.3. Leukemia
12.4.4. Colorectal Cancer
12.4.5. Others
12.5. Market Value Forecast By Country/Sub-region, 2015-2025
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Drug Type
12.6.2. By Therapy Type
12.6.3. By Cancer Type
12.6.4. By Country/Sub-region

13. Middle East & Africa Anticancer Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.1.2. Key Trends
13.2. Market Value Forecast By Drug Type , 2015-2025
13.2.1. Cytotoxic Drugs
13.2.1.1. Alkylating Agents
13.2.1.2. Antimetabolites
13.2.1.3. Others
13.2.2. Targeted Drugs
13.2.2.1. Monoclonal Antibodies
13.2.2.2. Tyrosine Kinase Inhibitors
13.2.2.3. Others
13.2.3. Hormonal Drugs
13.3. Market Value Forecast By Therapy Type , 2015-2025
13.3.1. Chemotherapy
13.3.2. Targeted Therapy
13.3.3. Immunotherapy
13.3.4. Others
13.4. Market Value Forecast By Cancer Type , 2015-2025
13.4.1. Lung Cancer
13.4.2. Breast Cancer
13.4.3. Leukemia
13.4.4. Colorectal Cancer
13.4.5. Others
13.5. Market Value Forecast By Country/Sub-region, 2015-2025
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of MEA
13.6. Market Attractiveness Analysis
13.6.1. By Drug Type
13.6.2. By Therapy Type
13.6.3. By Cancer Type
13.6.4. By Country/Sub-region

14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis By Company (2016)
14.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
14.3.1. F. Hoffmann-La Roche Ltd
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Eli Lilly and Company
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Novartis AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Pfizer Inc
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Bayer AG
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. AstraZeneca
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.7. Takeda Pharmaceutical Company Limited
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Merck & Co., Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. CELGENE CORPORATION
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Amgen Inc
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll